Very late-onset membranous nephropathy secondary to alemtuzumab in a patient with multiple sclerosis

Introduction Inflammatory bowel disease (IBD), which mainly includes Crohn’s disease and ulcerative colitis, is characterised by chronic inflammation in the gastrointestinal tract, triggered and perpetuated by an altered immune response. An association has been established […]

Introduction This article analyses the presence of gender bias in clinical trials of monoclonal antibodies used to treat multiple sclerosis. Material and methods We performed a systematic review of controlled clinical trials of 4 monoclonal […]

Background Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSDs) are characterized by relapses that contribute to accumulating disability. Over the past decade, monoclonal antibodies have increasingly replaced standard interventions (placebo or conventional immunosuppressants) due […]